Alpha Cognition Inc (ACOG)vsNovartis AG ADR (NVS)
ACOG
Alpha Cognition Inc
$5.87
-5.32%
HEALTHCARE · Cap: $127.81M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 553485% more annual revenue ($56.58B vs $10.22M). NVS leads profitability with a 23.9% profit margin vs -202.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ACOG
Avoid22
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -40.7% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ACOG
The primary concerns for ACOG are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ACOG profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.52 — expect wider price swings.
ACOG is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 22/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is an innovative biopharmaceutical firm focused on developing advanced therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its flagship product, ACOG-100, aims to improve cognitive function and fulfill critical unmet medical needs among the aging population. Leveraging a proprietary neuroscience platform and a comprehensive R&D strategy, the company is poised to make significant strides in patient care. As Alpha Cognition progresses with its clinical pipeline and explores new therapeutic options, it presents an appealing investment opportunity for institutional investors seeking to engage with the transformative healthcare sector.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?